Dasatinib + Quercetin

DRUG3 trials

Sponsors

Wake Forest University Health Sciences, The University of Texas Health Science Center at San Antonio, Washington University School of Medicine

Conditions

Alzheimer DiseaseAlzheimer Disease, Early OnsetIdiopathic Pulmonary Fibrosis (IPF)Mild Cognitive Impairment

Phase 1

Targeting Pro-Inflammatory Cells in Idiopathic Pulmonary Fibrosis: a Human Trial

CompletedNCT02874989

Wake Forest University Health SciencesIdiopathic Pulmonary Fibrosis (IPF)

Start: 2016-12-16End: 2019-06-03Updated: 2020-05-12

Senolytic Therapy to Modulate Progression of Alzheimer's Disease

CompletedNCT04063124

The University of Texas Health Science Center at San AntonioAlzheimer Disease

Start: 2020-02-14End: 2023-01-30Updated: 2023-03-06

Phase 2

Senolytic Therapy to Modulate the Progression of Alzheimer's Disease (SToMP-AD) Study

Active, not recruitingNCT04685590

Washington University School of MedicineAlzheimer Disease, Early Onset, Mild Cognitive Impairment

Start: 2021-12-22End: 2029-01-01Target: 48Updated: 2026-04-01

Related Papers

The Dual Role of Tau in Neuroprotection and Disease: Neuronal Senescence as a Therapeutic Target

Alzheimer s & Dementia2025-12-01

Evaluation of exploratory fluid biomarkers from a phase 1 senolytic trial in mild Alzheimer’s disease

Neurotherapeutics2025-04-238 citations

SPATIAL PROFILING CELLULAR SENESCENCE IN THE HUMAN BRAIN ACROSS EIGHT DECADES OF LIFE

Innovation in Aging2023-12-01

Senolytic therapy in mild Alzheimer's disease: a phase 1 feasibility trial.

2023-09-07165 citations

Senolytics dasatinib and quercetin in idiopathic pulmonary fibrosis: results of a phase I, single-blind, single-center, randomized, placebo-controlled pilot trial on feasibility and tolerability.

2023-02-28152 citations

Multi-targeted anti-inflammatory drugs for the treatment of neurological disorders

Neural Regeneration Research2022-09-213 citations

Senolytic Therapy to Modulate the Progression of Alzheimer's Disease (SToMP-AD): A Pilot Clinical Trial

The Journal of Prevention of Alzheimer s Disease2021-11-22174 citations

A geroscience motivated approach to treat Alzheimer's disease: Senolytics move to clinical trials.

2021-10-2122 citations

Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease.

2019-09-18951 citations

Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study.

2019-01-05892 citations